Seroprevalence of antibodies against fHbp and NadA, two potential vaccine antigens for Neisseria meningitidis (Q84346977)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19654065%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

title

Seroprevalence of antibodies against fHbp and NadA, two potential vaccine antigens for Neisseria meningitidis (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19654065%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

main subject

Neisseria meningitidis

1 reference

Susanne Jacobsson

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19654065%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

Paula Mölling

series ordinal

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19654065%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

Per Olcén

series ordinal

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19654065%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

publication date

3 August 2009

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19654065%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19654065%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

volume

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19654065%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

issue

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19654065%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

page(s)

5755-5759

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19654065%20AND%20SRC:MED&resulttype=core&format=json

Epidemic meningitis, meningococcaemia, and Neisseria meningitidis

4 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.056

Optimising the use of conjugate vaccines to prevent disease caused by Haemophilus influenzae type b, Neisseria meningitidis and Streptococcus pneumoniae

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.056

Haemophilus influenzae type b conjugate vaccine use and effectiveness

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.056

Pneumococcal vaccines: mechanism of action, impact on epidemiology and adaption of the species

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.056

Vaccination against meningococcal disease in Europe: review and recommendations for the use of conjugate vaccines.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.056

A surveillance network for meningococcal disease in Europe.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.056

Mathematical modelling of infection and disease due to Neisseria meningitidis and Neisseria lactamica.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.056

Development of natural immunity to Neisseria meningitidis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.056

Cross-Antigenicity and Immunogenicity between Capsular Polysaccharides of Group C Neisseria meningitidis and of Escherichia coli K92

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.056

Human immunity to the meningococcus. II. Development of natural immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.056

Antigenic Relationship between Escherichia coli and Neisseria meningitidis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.056

Bactericidal Antibody after Colonization with Neisseria meningitidis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.056

Meningococcal tetravalent conjugate vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.056

Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.056

MeNZB: a safe and highly immunogenic tailor-made vaccine against the New Zealand Neisseria meningitidis serogroup B disease epidemic strain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.056

A universal vaccine for serogroup B meningococcus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.056

Vaccine potential of the Neisseria meningitidis 2086 lipoprotein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.056

Distribution and genetic variability of three vaccine components in a panel of strains representative of the diversity of serogroup B meningococcus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.056

Sequence constancies and variations in genes encoding three new meningococcal vaccine candidate antigens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.056

The meningococcal vaccine candidate GNA1870 binds the complement regulatory protein factor H and enhances serum resistance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.056

Vaccination against Neisseria meningitidis using three variants of the lipoprotein GNA1870

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.056

NadA, a novel vaccine candidate of Neisseria meningitidis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.056

NadA diversity and carriage in Neisseria meningitidis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.056

Neisseria meningitidis NadA is a new invasin which promotes bacterial adhesion to and penetration into human epithelial cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.056

Human monocytes/macrophages are a target of Neisseria meningitidis Adhesin A (NadA).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.056

IFN-gamma and R-848 dependent activation of human monocyte-derived dendritic cells by Neisseria meningitidis adhesin A.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.056

The protective level of serum antibodies to the capsular polysaccharide of Haemophilus influenzae type b

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.056

Haemophilus influenzae serotype b vaccine failure: what is the significance of antibody levels?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.056

The Stonehouse survey: nasopharyngeal carriage of meningococci and Neisseria lactamica

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.056

Genetic Analysis of Meningococci Carried by Children and Young Adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.056

Seroprevalence of bactericidal and anti-outer membrane vesicle antibodies to Neisseria meningitidis group B in England

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.056

Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.056

Putative vaccine antigens from Neisseria meningitidis recognized by serum antibodies of young children convalescing after meningococcal disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.056

Prevalence and sequence variations of the genes encoding the five antigens included in the novel 5CVMB vaccine covering group B meningococcal disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.056

Bacillus pumilus polysaccharide cross-reactive with meningococcal group A polysaccharide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.056

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VACCINE.2009.07.056

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19654065%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19654065%20AND%20SRC:MED&resulttype=core&format=json